Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abdominal, abnormal, acute, advice, AEs, AG, aggravated, anorexia, antihypertensive, appeal, arbitration, arm, article, assumption, atrial, attention, awaiting, bacteremia, bacteria, baseline, befall, belief, Benchmark, body, broader, Cantor, carcinoid, cardiac, cardiovascular, categorized, catheter, chest, circulating, cited, cohort, coli, commentary, commonly, compassionate, competitor, complaining, complaint, confusion, contest, contesting, convene, convened, convening, convertible, correlate, CRL, CRSP, CTC, CV, death, deep, dehydration, dichloride, died, dismissing, displayed, dosimetry, doubtful, durable, dyspnea, ECG, embolism, endpoint, EPLND, estate, exhausted, fatigue, febrile, ferrante, fever, fibrillation, finite, Fitzgerald, formal, frequent, Fuji, gland, headache, hearing, hematologic, hematuria, heretofore, Highland, hospitalized, hypoxia, ICB, Inborn, indefinite, infarction, INR, intangible, intubated, Journal, karen, kishbauch, kit, lab, laxated, leukopenia, leverage, lived, MACE, magnitude, mCRPC, Memorial, merit, mg, michael, mild, motion, MRI, muscle, myelodysplastic, myocardial, naive, Naldemedine, Naloxegol, nausea, neuroendocrine, neuropathy, neutropenia, neutropenic, Nuclear, OfferingSM, OMX, Onalta, Orange, outlicensed, overallotment, pancreatic, PFO, pneumonia, policing, postponed, proceeding, proportion, Protocol, protracted, published, pulmonary, quantitative, radiolabeled, radiopharmaceutical, rash, reaction, reassessed, RECIST, refractory, renal, replacement, replacing, resolved, respiratory, resuming, revealed, revert, RFBM, RP, Scherrer, septic, Shionogi, shock, simplified, site, SPA, statistically, Strep, subcontracting, Subsector, substitute, succeeding, suggested, superseded, suspected, tablet, tabular, tachycardia, Tangible, Tasmania, thereto, TR, trofolastat, tunnel, uncollectable, uncontrolled, underwriter, unilaterally, vein, ventilator, vigorously, vomiting, week, weekly, Xofigo, Zurich
Removed:
AHP, barrier, began, binding, briner, budgetary, capacity, carryback, cell, cliff, collected, concentrated, consultation, Deposit, earning, ending, goff, guaranteed, half, HIV, internalizing, kurt, neovasculature, occupy, pen, perpetual, Pfizer, phosphoinositide, Plant, predominantly, qualifying, recovered, refund, registering, repurchase, sector, solid, source, spend, stephen, studied, surface, undergoing, undiscounted, Union, unresolved, updated
Filing tables
Filing exhibits
- 10-K Annual report
- 12.1 Exhibit 12.1 Ratio
- 21.1 Exhibit 21.1 Subsidiaries of Progenics Pharmaceuticals, Inc.
- 23.1 Exhibit 23.1 Consent of Pricewaterhousecoopers LLP
- 23.2 Exhibit 23.2 Consent of Ernst & Young LLP
- 31.1 Exhibit 31.1 Certification
- 31.2 Exhibit 31.2 Certification
- 32.1 Exhibit 32.1 Certification
- 32.2 Exhibit 32.2 Certification
- 10.40 Exhibit 10.40
- Download Excel data file
- View Excel data file
Related press release
PGNX similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT
TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The undersigned Chief Executive Officer of Progenics Pharmaceuticals, Inc. (the "Company") does hereby certify as follows:
This annual report on Form 10-K of the Company for the period ended December 31, 2013 and filed with the Securities and Exchange Commission on the date hereof (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Mark R. Baker | |
Date: March 13, 2014 | Mark R. Baker Chief Executive Officer (Principal Executive Officer) |
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Progenics Pharmaceuticals, Inc. and will be retained by Progenics Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.